U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467629) titled 'QLS5212 for Participants With Advanced Solid Tumors' on March 08.
Brief Summary: This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Cancer
Intervention:
DRUG: QLS5212
An anti-trophoblast glycoprotein antibody-drug conjugate
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qilu Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....